ArticleInternational journal of clinical and experimental pathology2019
The prognostic value of homeobox B7 expression in patients with hepatocellular carcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic role of homeobox B7 (HOXB7) in hepatocellular carcinoma (HCC) is not clearly established. The present study aimed to evaluate the associations among the clinicopathological characteristics, HOXB7 expression, and the overall survival (OS) of patients with HCC. An immunohistochemical analysis was used to detect the expression level of HOXB7. In addition, the association between the expression of HOXB7 and the clinicopathological characteristics of HCC was analyzed. The Kaplan-Meier method was used to calculate the survival rates, and the COX proportional hazards model was used to investigate univariate and multivariate analyses. A total of 80 patients were enrolled in this study. Of the 80 HCC samples, HOXB7 was up-regulated in 28 samples (35.0%). The high HOXB7 expression was significantly associated with OS by univariate Cox regression analysis (HR = 2.0; 95% CI = 1.1-3.4, P = 0.016). The median survival with high HOXB7 expression and low HOXB7 expression was 12.5 months ± 3.7 months versus 32.5 months ± 4.7 months, respectively, as visualized on Kaplan-Meier curves (P = 0.014). After adjusting for possible factors related to survival time after HCC resection, the results suggested that survival time was negatively correlated with high HOXB7 expression (HR = 2.592, 95% CI = 1.283-5.239, P = 0.008). The present data indicate that the HOXB7 expression was negatively associated with survival time after HCC resection. As HOXB7 was a common and readily available measurement in the clinical setting, it was a convenient and feasible way to identify those patients who were at high risk and who had a poor prognosis.
Indexed as
Identifiers
31934098PMC6949547W3007917677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.